Taken together, the current study reveals a significant role of APE1 in EGFR‐TKI resistance via novel regulatory effects on EMT in NSCLC and provides evidence supporting the involvement of APE1 in a malignant progression through EMT. Here, APEX1 is linked to non-small cell lung carcinoma.